

Agenda: Ontario Steering Committee for Cancer Drugs (OSCCD)

Date: November 23, 2020

Time: 1:00-2:30pm

Time	Topic	Description	Presenter(s)
1:00-1:15	<ul style="list-style-type: none">• Welcome• Agenda and Objectives• COI Declarations	Inform members of current status	Interim Chair
1:15-2:20	<ul style="list-style-type: none">• Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) for previously untreated mantle cell lymphoma patients who are ineligible for autologous stem cell transplantation	Submission	Lead/Clinical Presenter PE Presenter
2:20-2:30	<ul style="list-style-type: none">• Closing remarks<ul style="list-style-type: none">○ Reminder to shred materials○ Housekeeping Items	Inform members	Interim Chair